Grifols Therapeutics Llc
Clinical trials sponsored by Grifols Therapeutics Llc, explained in plain language.
-
New study checks safety of weekly infusion for rare lung disease
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a weekly intravenous treatment for people with lung damage caused by Alpha-1 antitrypsin deficiency. About 290 adults who completed a prior study will receive the therapy for 2 more years. Researchers will monitor side effects and chang…
Phase: PHASE3 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Can a weekly infusion protect lungs in Alpha-1 emphysema?
Disease control OngoingThis study tests whether a weekly intravenous dose of Alpha-1 MP (a protein that protects the lungs) can slow the progression of emphysema in people with Alpha-1 antitrypsin deficiency. About 345 participants receive either 60 mg/kg, 120 mg/kg, or a placebo for 3 years. The main …
Phase: PHASE3 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control
Last updated May 11, 2026 20:39 UTC